4D-150 Phase 2 interim data shows 89% injection rate reduction, 77% injection-free at 24 weeks in wet AMD

4D Molecular Therapeutics, Inc.

Planned Phase 3 dose (3E10 vg/eye): 89% reduction in mean annualized injection rate; 77% injection-free at 24 weeks.
No 4D-150-related SAEs, no hypotony, retinal vasculitis, or choroidal effusions observed in any patient across trials (n=139).
BCVA improved by +4.2 letters from baseline at 3E10 dose; injection-free patients saw +4.7 letters; dose response favored higher dose.
Phase 1 patients (n=3) treated at 3E10 remained injection-free through ~2-2.5 years; BCVA and CST stable.
Expects to announce Phase 3 trial design in Sep 2024, initiate in Q1 2025; 52-week data and DME data due in H2 2024/early 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.